8-K current report · filed Aug 6, 2026

NOVAVAX INC (NVAX) 8-K Current Report: August 6, 2026

Item 2.02Item EX-99.1NVAX overview

Short answer

NOVAVAX INC (NVAX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.

NOVAVAX INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Press release issued August 6, 2026; detailed results in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $57M, down 76% year over year, reflecting the absence of prior-year $202M milestone and Takeda amendment benefits
  • Net loss $53M versus $107M net income, while cash, securities and restricted cash totaled $724M at June 30
  • Full-year adjusted revenue framework raised to $235M-$275M from $230M-$270M
  • Combined R&D and SG&A expense guidance reduced by $10M midpoint to $370M-$410M
  • Sanofi milestones offer upside: $125M for CIC trial initiation and $75M upon expected mid-2027 technology-transfer completion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other NOVAVAX INC 8-K filings

Get the next NVAX 8-K as it lands

Follow NVAX for push alerts, or ask the research agent what this filing means.